成纤维生长因子受体2在原发及复发成釉细胞瘤中的表达及意义

doi:10.19438/j.cjoms.2017.03.013

中国口腔颌面外科杂志 ›› 2017, Vol. 15 ›› Issue (3): 254-258.doi: 10.19438/j.cjoms.2017.03.013

成纤维生长因子受体2在原发及复发成釉细胞瘤中的表达及意义

唐渔，季彤

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科，上海市口腔医学重点实验室，上海 200011

收稿日期:2016-03-15 修回日期:2016-05-05 出版日期:2017-05-20 发布日期:2017-06-09
通讯作者: 国家自然科学基金（81671009）
作者简介:唐渔（1991-），女，硕士，E-mail:xiaoxiaoyuer925@163.com
基金资助:
季彤，E-mail: jitong70@hotmail.com

The relationship between fibroblast growth factor receptor type 2 and clinical characteristics of primary/recurrent ameloblastoma

TANG Yu, JI Tong.

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine；Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2016-03-15 Revised:2016-05-05 Online:2017-05-20 Published:2017-06-09

摘要/Abstract

摘要： 目的：检测成纤维细胞生长因子受体2（FGFR2）在颌骨原发及复发成釉细胞瘤中的表达，并探讨其与成釉细胞瘤临床特点尤其是侵袭和复发的关系。方法：选择手术切除的多囊型成釉细胞瘤患者64例共96例成釉细胞瘤组织，分为复发组（第1组，32例患者64例组织）和原发组（第2组，32例患者 32例组织），以10例正常牙囊组织为对照，采用免疫组织化学方法检测96例成釉细胞瘤组织及10例牙囊组织中FGFR2蛋白的表达。应用SAS9.3软件包分析FGFR2与成釉细胞瘤的关系。结果：96例成釉细胞瘤中均检测到FGFR2的表达，复发成釉细胞瘤组织中FGFR2的表达显著高于原发成釉细胞瘤；第1组中原发成釉细胞瘤的平均直径为4.02 cm，第2组中成釉细胞瘤的平均直径为3.1 cm（P<0.05）且最大直径为3.9 cm。上颌骨复发成釉细胞瘤中FGFR2的阳性率显著高于下颌骨复发成釉细胞瘤。结论：肿瘤复发与成釉细胞瘤的大小相关，直径大于3.9 cm的成釉细胞瘤较直径小于3.9 cm者更易复发，且复发成釉细胞瘤中FGFR2的阳性率显著高于原发成釉细胞瘤，表明FGFR2的表达与成釉细胞瘤的复发相关，可能是成釉细胞瘤局部复发的机制之一。

关键词: 颌骨, 原发成釉细胞瘤, 复发成釉细胞瘤, FGFR2

Abstract: PURPOSE: To detect the immunohistochemical expression of fibroblast growth factor receptor type 2 (FGFR2) in primary ameloblastoma and recurrent ameloblastoma, and to determine its role in development of ameloblastoma, especially in invasion and recurrence of ameloblastoma. METHODS: Ninety-six formalin-fixed, paraffin-embedded tissue blocks of ameloblastoma specimens from 32 patients who had two surgeries due to recurrence and 32 patients who had only one surgery were compared at protein expression level using immunohistochemistry for FGFR2 staining. Statistical analysis was performed by use of SAS 9.3 software package, to determine the relationship between the expression of FGFR2 and clinical parameters. RESULTS: FGFR2 immunostaining was evident in all specimens, the staining in recurrent ameloblastoma was significantly stronger than in primary ameloblastoma. Statistical analysis showed that FGFR2 expression was significantly higher in recurrent ameloblastoma than in primary ameloblastoma; FGFR2 expression was significantly higher in maxillary recurrent ameloblastoma than in mandibular recurrent ameloblastoma; patient with tumor size over 3.9 cm had a higher rate of recurrence. CONCLUSION: High expression of FGFR2 plays an important role in invasion and recurrence of ameloblastoma.

Key words: Jaw bone, Recurrent ameloblastoma, Primary ameloblastoma, FGFR2

中图分类号:

R739.8

唐渔，季彤. 成纤维生长因子受体2在原发及复发成釉细胞瘤中的表达及意义[J]. 中国口腔颌面外科杂志, 2017, 15(3): 254-258.

TANG Yu, JI Tong.. The relationship between fibroblast growth factor receptor type 2 and clinical characteristics of primary/recurrent ameloblastoma[J]. China J Oral Maxillofac Surg, 2017, 15(3): 254-258.

参考文献

[1] Almeida Rde A, Andrade ES, Barbalho JC, et al. Recurrence rate following treatment for primary multicystic ameloblastoma: systematic review and meta-analysis [J]. Int J Oral Maxillofac Surg, 2016, 45(3): 359-367.
[2] Rastogi V, Pandilwar PK, Maitra S. Ameloblastoma: an evidence based study [J]. J Maxillofac Oral Surg, 2010, 9(2): 173-177.
[3] Nakamura N, Higuchi Y, Mitsuyasu T, et al. Comparison of long-term results between different approaches to ameloblastoma [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002, 93(1): 13-20.
[4] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy [J]. Nat Rev Drug Discov, 2009, 8(3): 235-253.
[5] Wilkie AO, Morriss-Kay GM, Jones EY, et al. Functions of fibroblast growth factors and their receptors [J]. Curr Biol,1995, 5(5):500-507.
[6] Cormier S, Leroy C, Delezoide AL, et al. Expression of fibroblast growth factors 18 and 23 during human embryonic and fetal development [J]. Gene Expr Patterns, 2005, 5(4): 569-573.
[7] Li X, Wang C, Xiao J, et al. Fibroblast growth factors, old kids on the new block [J]. Semin Cell Dev Biol, 2016, 53: 155-167.
[8] Kettunen P, Laurikkal J, It ranta P, et al. Association of FGF-3 and FGF-10 with signaling networks regulating tooth morphogenesis [J]. Dev Dyn, 2000, 219(3): 322-332
[9] Klein OD, Lyons DB, Balooch G, et al. An FGF signaling loop sustains the generation of differentiated progeny from stem cells in mouse incisors [J]. Development, 2008, 135(2): 377-385.
[10] Han N, Kim MA, Lee HS, et al. Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer [J]. Pathobiology, 2015, 82(6): 269-279.
[11] Liu K, Song X, Zhu M, et al. Overexpression of contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts [J]. Oncol Lett, 2015, 10(4): 2003-2008.
[12] Mathur A, Ware C, Davis L, et al. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival [J]. PLoS One, 2014, 9(6): e98515.
[13] Meyer KB, Maia AT, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer [J]. PLoS Biol, 2008, 6(5): e108.
[14] Nomura S, Yoshitomi H, Takano S, et al. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer [J]. Br J Cancer, 2008, 99(2): 305-313.
[15] 李琳琳, 刘云鹏, 侯柯佐, 等. FGFR2和c-Cbl在胃癌组织中的表达及其临床意义 [J]. 中国癌症杂志, 2009, 19(8): 609-614.
[16] 覃山羽, 姜海行, 李信, 等. 胃癌及癌前病变中bFGF 、 FGFR-2及Hpa的表达及其意义[J]. 中国实用内科杂志, 2007, 27(17): 1379-1383.
[17] 郑永华, 牟一平, 张锐利, 等. 成纤维细胞生长因子2（FGFR2）在直肠癌中的表达意义[D]. 杭州: 浙江大学, 2011.
[18] Sato T, Oshima T, Yoshihara K, et al. Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer[J]. Oncol Rep, 2009, 21(1): 211-216.
[19] Brown NA, Rolland D, McHugh JB, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma [J]. Clin Cancer Res, 2014, 20(21): 5517-5526.
[20] Diniz MG, Gomes CC, Guimar es BV, et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours [J]. Tumour Biol, 2015,36(7): 5649-5653.
[21] Nakao Y, Mitsuyasu T, Kawano S, et al. Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway [J]. Int J Oncol, 2013, 43(5): 1377-1384.
[22] Martin AJ, Grant A, Ashfield AM, et al. FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype [J]. BMC Res Notes, 2011, 4: 72.
[23] Mcinerney N, Colleran G, Rowan A, et al. Low penetrance breast cancer predisposition SNPs are site specific [J]. Breast Cancer Res Treat, 2009, 117(1): 151-159.

成纤维生长因子受体2在原发及复发成釉细胞瘤中的表达及意义

The relationship between fibroblast growth factor receptor type 2 and clinical characteristics of primary/recurrent ameloblastoma

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	金夏悦, 顾迎新. 骨质疏松对口腔种植修复影响的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 81-86.
[2]	李晓妮, 官群立, 林锡江, 王耀钟. 上颌前牙区囊肿髂骨植骨术后种植修复1例5年回顾[J]. 中国口腔颌面外科杂志, 2023, 21(1): 92-96.
[3]	寻兴祥, 孙伟, 王荷静, 楚晨, 赵谦, 许晓, 袁荣涛. 用于颌骨缺损修复的可注射多功能脂质体-水凝胶复合体的构建及体外评价[J]. 中国口腔颌面外科杂志, 2022, 20(6): 534-540.
[4]	顾雨薇, 王凤, 黄伟, 张志勇, 张陈平, 孙坚, 吴轶群. 种植联合血管化髂骨移植重建14例下颌骨缺损的长期疗效观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 422-428.
[5]	刘舒畅, 张兆强, 黄洪章, 刘习强. 放射性颌骨坏死术后感染预警模型的建立与验证[J]. 中国口腔颌面外科杂志, 2022, 20(5): 471-476.
[6]	顾雨薇, 王凤, 黄伟, 张志勇, 张陈平, 孙坚, 吴轶群. 种植联合血管化髂骨移植重建14例下颌骨缺损的长期疗效观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 488-493.
[7]	孟昭松, 李小囡, 董瑞, 张健. 下颌骨不典型神经鞘瘤1例报告[J]. 中国口腔颌面外科杂志, 2022, 20(5): 510-512.
[8]	马玉洁, 余敏杰, 宋赛文, 张馨月, 蔡宜倞, 陈洁, 袁勇翔, 蒋灿华. 外伤致下颌骨髁突颅内移位：病例报告及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(5): 513-516.
[9]	王楚瑶, 邹璐芗, 陆川, 何冬梅. miR-330-3p在颞下颌关节骨关节炎软骨退变中的作用机制研究[J]. 中国口腔颌面外科杂志, 2022, 20(4): 320-327.
[10]	李辉, 黄林剑, 谢千阳, 杨驰. 体外培养的兔下颌骨髁突对机械压力的反应和变化[J]. 中国口腔颌面外科杂志, 2022, 20(4): 340-346.
[11]	杨金刚, 夏荣辉, 朱云, 吴思成, 董亚兵, 杨功鑫, 史俊隆, 崔迎慧, 朱凌, 周晌辉. 98例原发性颌骨内鳞状细胞癌预后影响因素的回顾性分析[J]. 中国口腔颌面外科杂志, 2022, 20(3): 239-243.
[12]	王磊, 王周阳, 马春跃, 王良, 郭兵, 秦兴军. 2种开窗减压术治疗大型下颌骨牙源性囊肿的效果比较[J]. 中国口腔颌面外科杂志, 2022, 20(1): 58-62.
[13]	胡龙威, 颜然, 文晋, 张陈平, 赵小妹, 李思毅. 127例药物性颌骨坏死患者回顾性分析：单中心10年经验总结[J]. 中国口腔颌面外科杂志, 2022, 20(1): 72-76.
[14]	杨宗燕, 康一帆, 吕晓鸣, 张雷, 单小峰, 蔡志刚. 血管化髂骨瓣重建下颌骨有牙区缺损时髂骨嵴不同朝向的优缺点比较[J]. 中国口腔颌面外科杂志, 2021, 19(5): 434-438.
[15]	徐晓峰, 朱方兴, 廖倩, 徐兵, 沈国芳, 张文斌, 史俊. 75例下颌骨粉碎性骨折的治疗效果评价[J]. 中国口腔颌面外科杂志, 2021, 19(5): 456-459.